Carregant...
Successful Treatment of Advanced Metastatic Prostate Cancer following Chemotherapy Based on Molecular Profiling
After Taxotere fails, treatment options for metastatic prostate cancer are limited. The three drugs with FDA approval in this setting, Jevtana, Provenge and Zytiga, are associated with median survivals of less than 2 years. In part, the impact on survival is the result of low response rates, indicat...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
S. Karger AG
2012
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3364088/ https://ncbi.nlm.nih.gov/pubmed/22666205 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000338077 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|